Clinical trials: Relapsed Adult ALL
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Relapsed/Refractory B-cell Malignancies
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
The primary objective of this study is to determine the long-term safety and tolerability of tirabrutinib in adults with relapsed/refractory B-cell malignancy who have tolerated and achieved stable disease or improved with…
- Trial name
- NCT02457559
- Testing
- Tirabrutinib
- Where
- 6 sites in France, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Gilead Sciences
Solid Tumor, Unresectable or Metastatic Melanoma
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
- Trial name
- NCT03993379
- Testing
- CX-072, Ipilimumab
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- CytomX Therapeutics
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies how well decitabine and total-body irradiation followed by donor bone marrow transplant and cyclophosphamide works in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01707004
- Testing
- decitabine, fludarabine phosphate, busulfan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Multiple Myeloma
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT00963820
- Testing
- Ixazomib citrate
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia (CLL)
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell…
- Trial name
- NCT01466153
- Testing
- Rituximab, Bendamustine, MEDI-551
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 183 people
- Sponsor
- MedImmune LLC
Relapsed or Refractory Multiple Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
- Trial name
- NCT03512353
- Testing
- Dexamethasone, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01466179
- Testing
- Blinatumomab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 225 people
- Sponsor
- Amgen Research (Munich) GmbH
Solid Tumors, Lymphoma
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Background: The new drug LMP744 (NSC 706744) damages deoxyribonucleic acid (DNA). This causes cell death. Researchers want to see if it can treat certain kinds of cancer.
- Trial name
- NCT03030417
- Testing
- LMP744, Ondansetron, Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoid Leukemia, Acute Lymphoblastic Leukemia
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes.
- Conditions
- Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Trial name
- NCT03575325
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Immune Thrombocytopenia
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
This was a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/μL on two…
- Trial name
- NCT03395210
- Testing
- Rilzabrutinib
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 86 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Adult T Cell Leukemia, Adult T Cell Lymphoma
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
This clinical trial will be a multicenter phase II fixed-dose trial in which a minimum of 10 patients with immunophenotypically confirmed ATL with at least 50% of the blasts expressing CD25 as measured by flow cytometry at…
- Trial name
- NCT01378871
- Testing
- IMTOX-25
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amit Verma
Leukemia, Myelodysplastic Syndromes
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant
The goal of this study is to see if there is a benefit to giving chemotherapy and then natural killer (NK) cells. The NK cells must come from a family member who shares half of the patients HLA proteins.
- Trial name
- NCT00526292
- Testing
- natural killer cell therapy, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
This randomized phase II trial studies how well cytarabine with or without SCH 900776 works in treating adult patients with relapsed acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT01870596
- Testing
- Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2…
- Trial name
- NCT04524455
- Testing
- Blinatumomab, AMG 404, Dexamethasone Premedication
- Where
- 19 sites in United States, Australia and 7 more
- Volunteers
- 17 people
- Sponsor
- Amgen
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial is studying how well AKT inhibitor MK-2206 works in treating patients with relapsed or refractory acute myeloid leukemia (AML).
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01253447
- Testing
- Akt inhibitor MK2206, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT04776018
- Testing
- TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
- Where
- 13 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Takeda
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar